RxDoctor Payments DataLook up a doctor →

Cheryl Smith, PhD

Neurology · Morgantown, WVNPI 1396037966

Payments from drug & device makers

$394,394in general payments, 2019–2025

Across 535 payments — averaging $737.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$204K
  • AstraZeneca$95K
  • Sanofi US Services Inc.$54K
  • UCB, Inc.$22K
  • Argenx US, Inc.$8K
  • Catalyst Pharmaceuticals, Inc.$4K
  • plus $7K from 47 others

What the payments were for

  • Consulting fees$32,87048%
  • Speaking & faculty fees$17,23025%
  • Travel & lodging$7,39511%
  • Food & beverage$10,87316%
  • Education$680%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$394,394 in reported general payments places this provider in the 95th percentile of 93 neurology providers in West Virginia.

See all neurology providers in West Virginia

Medicare billing

Part B allowed, 2024
$193,903
Medicare patients
421
Services billed
6,565

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PanzygaImmun Glob G(Igg)-Ifas/Glycine16$141,550
Memantine Hcl ErMemantine Hcl12$3,332
Mycophenolate Mofetil12$1,832
Pyridostigmine Bromide18$1,692
Memantine Hcl40$1,498
Mirtazapine27$1,119
Gabapentin44$619
Carbidopa-LevodopaCarbidopa/Levodopa20$568
Donepezil Hcl46$510
Amitriptyline Hcl15$392
Phenytoin Sodium Extended11$296
Carbidopa-Levodopa ErCarbidopa/Levodopa12$291
Levetiracetam11$246
Methylprednisolone Sodium SuccMethylprednisolone Sod Succ13$175
Pregabalin11$169

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPanzyga$426$141,55016 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide$232$3,52330 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 93 neurology providers in West Virginia.

Other neurology in Morgantown

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →